STOCK TITAN

Resverlogix - RVXCF STOCK NEWS

Welcome to our dedicated page for Resverlogix news (Ticker: RVXCF), a resource for investors and traders seeking the latest updates and insights on Resverlogix stock.

Resverlogix Corp. (RVXCF) is a Calgary based late-stage biotechnology company and the world leader in epigenetics, founded in 2001. The company's main focus is on developing first-in-class therapies for patients with chronic diseases. Resverlogix is known for its lead epigenetic candidate, apabetalone (RVX-208), a BD2 selective BET inhibitor with an epigenetic mechanism of action. Apabetalone has shown promising results in multiple diseases, including cardiovascular disease, diabetes, post-COVID-19 conditions, and more. Resverlogix has collaborated with EVERSANA™ to support the rapid commercialization of apabetalone in Canada and the United States.

Rhea-AI Summary

Resverlogix Corp. (TSX: RVX) presented at the European Society of Cardiology (ESC) Congress 2024, highlighting apabetalone's potential cardioprotective benefits. Key points include:

1. Apabetalone reduced MACE and heart failure hospitalization hazard by 63% (p=0.0002) in patients taking next-generation glucose-lowering drugs.

2. Independent researchers presented data on apabetalone's benefits for vascular dysfunction, heart failure, cellular aging, and pulmonary arterial hypertension.

3. The company positions apabetalone as a drug with potential benefits across various metabolic diseases, including cardiovascular disease, chronic kidney disease, inflammation, and diabetes.

4. Resverlogix plans to demonstrate apabetalone's efficacy in combination with SGLT2 inhibitors in the upcoming BETonMACE2 trial.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
none
-
Rhea-AI Summary

Resverlogix Corp. (TSX: RVX) held its Annual & Special Meeting of Shareholders on July 31, 2024, in Calgary, Alberta. Shareholders elected four Board members and approved all resolutions outlined in the Notice of Meeting and Management Information Circular. The voting results showed strong support for all directors, with approval rates ranging from 95.11% to 95.91%.

Additionally, Resverlogix announced the closing of a two-year extension of its US$6.0 million secured debenture with Shenzhen Hepalink Pharmaceutical Group Co., This extension provides the company with continued financial stability. The Information Circular is available on SEDAR and the Resverlogix website, and a webcast archive of the executive presentation is accessible online.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Resverlogix Corp. (TSX: RVX) has announced a two-year extension of its US$6.0 million secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group Co., The maturity date has been extended to May 13, 2026. Key changes include:

1. Elimination of Hepalink's conversion privileges
2. Increase in interest rate from 12% to 18% per annum, effective May 14, 2024
3. Additional reporting requirements for Resverlogix
4. Continuation of normal business operations

The amendment is subject to Toronto Stock Exchange and shareholder approval. Shareholders will vote on the amendments at Resverlogix's annual and special meeting on July 31, 2024. Hepalink has agreed to forbear from enforcing the debenture, contingent on shareholder approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Resverlogix has rescheduled its Annual and Special Meeting of Shareholders to July 31, 2024, at 1:00 PM MT, from its original date of June 27, 2024. Shareholders will receive a Notice of Meeting and Management Information Circular detailing the matters to be discussed. These documents will also be available on SEDAR+ at www.sedarplus.ca. Following the formal business proceedings, Resverlogix will present a corporate update.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Resverlogix Corp. (TSX: RVX) announced a two-year extension of its US$6.0 million secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group. The new maturity date is May 13, 2026.

Along with the extension, Hepalink's conversion privileges have been eliminated, and the interest rate has increased from 12% to 18% per annum, starting May 14, 2024. The changes are subject to execution of definitive transaction documents, customary closing conditions, and Toronto Stock Exchange approval.

CEO Donald McCaffrey expressed appreciation for Hepalink's continued support.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Resverlogix Corp. (RVXCF) announces the resignation of Shawn Lu from the Board of Directors, effective immediately. The President and CEO, Donald McCaffrey, expressed gratitude for Lu's contributions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Rhea-AI Summary
Resverlogix Corp. (TSX: RVX) announced the publication of the 40th peer-reviewed scientific journal article on apabetalone's potential therapeutic benefits. The articles cover a wide range of topics, including the treatment of cardiovascular disease, diabetes, post-COVID-19 conditions, chronic kidney disease, and rare diseases. The company has a strong publication record in prestigious scientific journals, demonstrating the potential of apabetalone in various medical conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Resverlogix Corp. announces positive results for apabetalone in the treatment of facioscapulohumeral muscular dystrophy (FSHD) in a peer-reviewed article. Apabetalone inhibits DUX4 activity and reverses its gene expression in muscle cells, offering potential benefits for FSHD patients. The article highlights the lack of approved therapeutics for FSHD and the positive safety profile of apabetalone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Resverlogix Corp. announces new guidelines by the European Society of Cardiology highlight the opportunity for apabetalone to benefit high-risk patients with type 2 diabetes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of Resverlogix (RVXCF)?

The current stock price of Resverlogix (RVXCF) is $0.0321 as of February 28, 2025.

What is the market cap of Resverlogix (RVXCF)?

The market cap of Resverlogix (RVXCF) is approximately 11.2M.

What is Resverlogix Corp. known for?

Resverlogix is known for being a world leader in epigenetics and developing first-in-class therapies for patients with chronic diseases.

What is apabetalone?

Apabetalone (RVX-208) is Resverlogix's lead epigenetic candidate, a BD2 selective BET inhibitor with an epigenetic mechanism of action.

What diseases has apabetalone shown promising results in?

Apabetalone has shown promising results in cardiovascular disease, diabetes, post-COVID-19 conditions, and more.

Who has Resverlogix collaborated with for commercialization?

Resverlogix has partnered with EVERSANA™ to support the rapid commercialization of apabetalone in Canada and the United States.

What is Resverlogix's main aim with its therapies?

Resverlogix aims to improve patients' lives by restoring biological functions altered by serious illnesses like cardiovascular disease back to a healthier state.

What is Resverlogix's lead candidate for treatment?

Resverlogix's lead candidate for treatment is apabetalone (RVX-208), a BD2 selective BET inhibitor with an established safety record.

What makes apabetalone unique?

Apabetalone is the only drug of its class that is well tolerated for chronic administration, with over 4200 patient-years of safety data across ten trials.

What recent publication highlights are associated with apabetalone?

Recent publication highlights include evidence of apabetalone's potential in the treatment of cardiovascular disease, diabetes, post-COVID-19 conditions, chronic kidney disease, and more.

What is Resverlogix's main area of focus in its clinical program?

Resverlogix's clinical program is focused on evaluating apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions.

When was Resverlogix founded and what is its goal?

Resverlogix was founded in 2001 with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.
Resverlogix

OTC:RVXCF

RVXCF Rankings

RVXCF Stock Data

11.23M
161.33M
42.08%
Biotechnology
Healthcare
Link
Canada
Calgary